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Abstract
Background: Autism spectrum disorders (ASD) are a group of severe childhood neurodevelopmental disorders with still
unknown etiology. One of the most frequently reported associations is the presence of recurrent de novo or inherited
microdeletions and microduplications on chromosome 16p11.2. The analysis of rare variations of 8 candidate genes among
the 27 genes located in this region suggested SEZ6L2 as a compelling candidate.
Methodology/Principal Findings: We further explored the role of SEZ6L2 variations by screening its coding part in a group
of 452 individuals, including 170 patients with ASD and 282 individuals from different ethnic backgrounds of the Human
Genome Diversity Panel (HGDP), complementing the previously reported screening. We detected 7 previously unidentified
non-synonymous variations of SEZ6L2 in ASD patients. We also identified 6 non-synonymous variations present only in
HGDP. When we merged our results with the previously published, no enrichment of non-synonymous variation in SEZ6L2
was observed in the ASD group compared with controls.
Conclusions/Significance: Our results provide an extensive ascertainment of the genetic variability of SEZ6L2 in human
populations and do not support a major role for SEZ6L2 sequence variations in the susceptibility to ASD.
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Introduction
The autism spectrum disorders (ASD) are characterised by
impairments in reciprocal social communication, and repetitive,
stereotyped and ritualistic verbal and non-verbal behaviours [1].
Beyond this unifying definition lies an extreme degree of clinical
heterogeneity, ranging from profound to moderate impairments.
ASD include autism, Asperger syndrome and pervasive develop-
mental disorder not otherwise specified (PDD-NOS). The
prevalence of ASD overall is about 1/100, but closer to 1/300
for typical autism [2]. Twin and family studies have conclusively
described ASD as the most ‘‘genetic’’ of neuropsychiatric
disorders, with concordance rates of 82–92% in monozygotic
twins versus 1–10% in dizygotic twins, and a sibling recurrence
risk of 6% [3,4]. Several genes associated with ASD appear to be
involved in synapse formation and/or maintenance, suggesting a
common pathway in the susceptibility to these heterogeneous
disorders [5,6].
Chromosomal rearrangements have been recurrently associated
with ASD. De novo, or inherited, submicroscopic microdeletion/
duplication at the 16p11.2 chromosomal region are among the
most frequently observed: 1% of ASD patients [7,8,9]. A meta-
analysis and an additional screening provided support for the role
of recurrent 16p11.2 deletions and duplications as a risk factor for
ASD (deletions in 17/2172 ASD cases versus 9/28406 controls,
P=2.3610
213; duplications in 10/2172 ASD cases versus 8/
28406 controls, P=1.9610
27) [10]. Duplications of 16p11.2 have
been identified in 0.3% of patients with schizophrenia
(P=4.8610
27) and 0.12% of patients with bipolar disorders
(P=0.017), suggesting that 16p11.2 micro-rearrangements may be
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17289a vulnerability factor shared by patients with ASD, schizophrenia
and bipolar disorders [10].
The critical 16p11.2 region spans 500–600 kb and is flanked by
147 kb highly similar (.99% homology) low copy repeats, that
predispose this region to unequal crossing-over during meiosis.
The region contains 27 genes that code for proteins, and
apparently harbors no miRNAs. At least 17 of the genes are
expressed in the brain and/or may play a role in neurodevelop-
ment. To identify the causative genes for ASD, Kumar et al. (2009)
screened for rare variations in 8 candidate genes that were selected
based on their expression in the brain and function: ALDOA,
DOC2A, HIRIP3, MAPK3, MAZ, PPP4C, SEZ6L2 and TAOK2
[11]. None of these genes showed a strongly significant association
with ASD. However, a suggestive association was detected
between the R386H non-synonymous variant in the SEZ6L2 gene
(seizure related 6 homolog (mouse)-like 2) and ASD (12/1106 ASD
cases versus 3/1161 controls; P=0.018). SEZ6L2 is a compelling
candidate gene for ASD due to the high level of expression in the
brain and the strong homology of the protein with SRPX2 (Sushi-
repeat-containing protein, X-linked), whose gene mutations causes
epilepsy and language disorders [12]. Indeed, the prevalence of
seizures in patients with ASD is between 5–38%, with the frequent
observation of epileptiform activity, even without clinical epilepsy
[13].
The aim of our study was to explore the genetic variability of
SEZ6L2 in an independent group of ASD patients. Since Kumar
et al. (2009) had already sequenced a large sample of controls of
European ancestry (n=93–1731, depending on the exon), we
chose to extend the mutation screening to other ethnic
backgrounds from the Human Genome Diversity Panel (HGDP),
to ascertain whether the variations identified in ASD are
independent of the ethnic ancestry.
Results and Discussion
We detected seven variations that are unique to ASD patients
and six HGDP-specific ones. Furthermore, we found a single
variation in both study groups (Table 1, Figure 1). When we
merged our ASD screening results with those of Kumar et al.
(2009), it could be concludes that ten non-synonymous variations
Table 1. Details and consequences of non-synonymous variations in the SEZ6L2 gene identified in two independent sample set of
patients with ASD, HGDP, and in ASD and control groups of Kumar et al. (2009).
Amino Acid Change Functional prediction PolyPhen-2/SIFT This study Kumar et al. (2009)
ASD HGDP ASD Controls
ASD only
G84S Benign/damaging 1/170
a 0/282 0/527 0/278
P90L Damaging/damaging 2/170
a 0/282 0/527 0/278
S396L Damaging/tolerated 0/170 0/282 1/1099 0/1152
R482H Damaging/tolerated 1/170
a 0/282 0/93 0/93
D504S Benign/tolerated 1/170
a 0/282 0/93 0/93
P588L Benign/tolerated 0/170 0/282 1/527 0/278
P724L Damaging/tolerated 0/170 0/282 1/527 0/554
L734Q Benign/tolerated 0/170 0/282 1/527 0/554
E740Q Benign/tolerated 1/170
a 0/282 0/527 0/554
R796C Damaging/tolerated 1/170
a 0/282 0/527 0/554
ASD and controls
V193I Benign/tolerated 1/170
a 0/282 0/527 2/278
R386H Benign/tolerated 0/170 1/282
a 12/1106 3/1161
D518N Damaging/tolerated 4/170
a 1/282
a 0/93 0/93
Controls only
G71E Damaging/damaging 0/170 1/282
b 0/527 0/278
P81L Damaging/damaging 0/170 0/282 0/527 1/278
R113T Damaging/tolerated 0/170 1/282
a 0/527 0/278
G234S Benign/tolerated 0/170 0/282 0/527 1/278
V273I Benign/tolerated 0/170 2/282
b 0/527 1/278
P296L Benign/damaging 0/170 1/282 0/527 0/278
R716C Damaging/damaging 0/170 0/282 0/527 1/554
A765T Benign/tolerated 0/170 0/282 0/527 1/554
E778K Benign/tolerated 0/170 1/282
b 0/527 0/554
H817R Damaging/tolerated 0/170 0/282 0/527 1/554
P886H Damaging/tolerated 0/170 1/282
c 0/527 0/278
aEuropean/Middle East.
bAfrica (Mandenka).
cAsia.
doi:10.1371/journal.pone.0017289.t001
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observed in the control group and one was found in both groups
(Table 1). Six of the 10 variations only reported in ASD (G84S,
P90L, S396L, R485H, P724L and R796C) were predicted as
probably damaging by the PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph/index.html) and/or SIFT (http://sift.jcvi.org)
programs.
In our cohort of patients, variations were inherited from healthy
parents, with the exception of one that was transmitted by a father
with Asperger syndrome (Figure 2). No significant difference
between maternal (n=7) and paternal (n=5) transmission was
observed. Variations we found in ASD samples were each sparsely
distributed in only a small number of families and no common
phenotype was observed among the carriers. For example, the
G84S variation was maternally transmitted to a child with
Asperger syndrome (Family 1). The P90L variation, predicted by
both PolyPhen-2 and SIFT to be damaging, was found in 2
unrelated ASD families. In one family, the father transmitted this
variation to his daughter who suffered from typical autism and
intellectual disability (Family 2). This patient also carried a
pericentric inversion on chromosome 9, which has no pathological
consequences. The father’s cousin is suspected to have Asperger
syndrome, but his DNA was unavailable for this screening. In the
second family, the mother transmitted the P90L variation to her
son who had Asperger syndrome and obsessive–compulsive
disorder (Family 3). A history of epilepsy was reported in neither
family. In our study, the V193I variant was only observed in a
single patient of Caucasian origin (Family 4). The same variation
had already been detected in two Caucasian controls by Kumar
et al. (2009) [11]. The R485H variation transmitted by a dyslexic
father was observed in a child with Asperger syndrome and a high
IQ (Family 5). The D504S variant was inherited from a father and
Figure 1. Protein localization of SEZ6L2 non-synonymous variations detected in patients with ASD, controls and HGDP samples.
The changes predicted by PolyPhen-2 and/or SIFT as damaging for protein function, are indicated by underlined bold font. The variations found in
both ASD and in control and/or HGDP groups are indicated with an asterisk.
doi:10.1371/journal.pone.0017289.g001
Figure 2. Pedigrees of families with rare non-synonymous variants of the SEZ6L2 gene. Squares indicate males; circles indicate females.
The black colour indicates individuals with a diagnosis of autism, grey indicates Asperger syndrome, a mix of black and white indicates PDD-NOS, and
striped symbols represent depression. The variations found in control and/or HGDP groups are indicated with an asterisk.
doi:10.1371/journal.pone.0017289.g002
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The D518N variation was observed in 4 independent families with
ASD, and in 1 subject in the HGDP (French Basque). In one
family, the father transmitted the D518N variation to his two
children, who both had PDD-NOS and encephalographic
abnormalities (Family 7). In a second family, a boy with ASD
and intellectual disability inherited the D518N variation from his
mother, who was reported to suffer from a recurrent major
depressive disorder (Family 8). In a third family, D518N was
transmitted by another mother, with a major depressive disorder
to her son, who had PDD-NOS and mild intellectual disability
(Family 9). In a fourth large family, 3/4 children with Asperger
syndrome carried the D518N variation, as did 2/2 unaffected sibs
(Family 10). In this last case, this variation was inherited from the
father diagnosed with Asperger syndrome. The E740Q substitu-
tion was observed in an autistic child and his healthy father
(Family 11). The R796C variation was found in a single ASD
family (Family 12), being transmitted from the mother to her son
affected with autism, but not to her healthy son.
We also detected the two variations (R386H and E38E) that had
previously been identified in patients with ASD by Kumar et al.
(2009). The R386H variation was detected in a HGDP subject
(Sardinian origin), but not in our ASD patient group. The
synonymous E38E variation, that had previously been identified in
a child with a 16p11.2 deletion and had been proposed as a risk
allele, was detected in one patient (inherited from the mother).
This child is mainly non-verbal and has a comorbid moderate
intellectual deficit (IQ,50). We also identified this variation in two
HGDP individuals (Russian and Orkadian origins). We did not
find any of these variations in population samples from Africa, the
Middle East and Asia.
Taken together, our results merged with those previously
reported by Kumar et al. (2009) suggest that there is no significant
enrichment of non-synonymous variations in the SEZ6L2 gene in
ASD compared with geographically matched European controls.
In all but one family, variations were transmitted from unaffected
parents and did not fully segregate with the disorder. In addition,
in our patient group we did not detect the R386H variation that
had previously been associated with ASD, nor did we observe de
novo or non-sense mutations with putative functional impact. None
of the variations detected in our ASD group overlapped with those
reported by Kumar et al. (2009). Finally, when the predicted
functional impact of the variations was considered, no enrichment
in variations predicted to be damaging was observed in any of the
three study groups: ASD (5/10), controls (3/6) and HGDP (3/5).
In conclusion, our screening of three supplemental groups of
individuals from different ethnic backgrounds completes the
determination of the genetic variability of SEZ6L2. However, the
design of our study cannot formally exclude a causative role of the
SEZ6L2 gene.
One limitation of this study is the reduced power to detect
association. Indeed, no alleles of frequency .1% have so far been
definitively identified in ASD. Additionally, we lack functional
assays to detect the impact of the detected variants on SEZ6L2
function. Here, we used PolyPhen-2 that has been reported to
have a better prediction accuracy compared with the previous
version [14]. However, we cannot exclude that functional
approaches might yield a different result.
Finally, chromosomal rearrangements at 16p11.2 have been
recurrently observed in several distinct developmental neuro-
psychiatric disorders [10,15,16]. It becomes evident that
16p11.2 duplications/deletions represent a significant genetic
risk factor, but not sufficient by itself. Recent investigations
suggest a ‘‘two-hit model’’ to develop the disease [15]. The
decreasing cost of next-generation sequencing in the near future
will shed light on the burden of mutations in coding parts and
regulatory elements found in patients — not only for genes in
the 16p11.2 region, but also for other genes that may act as
additional hits.
Materials and Methods
We sequenced all exons of the SEZ6L2 gene in a sample of
452 individuals: 170 unrelated patients with ASD and 282
individuals from the Human Genome Diversity Panel (HGDP)
[17]. Patients with ASD were recruited by the Paris Autism
Research International Sibpair study at specialized clinical
centres in France and Sweden. Diagnosis was based on clinical
evaluation by experienced clinicians, using DSM-IV criteria, the
Autism Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS). In Sweden, in some
cases, the Diagnostic Interview for Social and Communication
Disorders (DISCO-10) was applied instead of the ADI-R. Pa-
tients with Asperger syndrome were evaluated using the
Asperger Syndrome Diagnostic Interview. Patients were includ-
ed after a clinical and medical check-up with psychiatric and
neuropsychological examination, standard karyotyping, fragile-X
testing and brain imaging and EEG whenever possible. This
study was approved by the local Institutional Review Board
(IRB) and written inform consent was obtained from all
participants of the study. The local IRB are the Comite ´s de
Protection des Personnes I ˆle-de-France VI Sis Ho ˆpital Pitie ´-
Salpe ˆtrie `re 75013 PARIS for France and the Sahlgrenska
Academy Ethics committee, University of Gothenburg for
Sweden. For all probands written inform consent was signed
by the patients or parents or the legal representative.
The ASD sample (n=170; 134 males, 36 females; 97 simplex and
73 multiplex families) included 154 unrelated patients with an
autistic disorder and 11 with Asperger syndrome. Five individuals
narrowly failed to reach the criteria for autistic disorders and were
consideredtohavePDD-NOS.Whenararevariationwasidentified,
segregation was studied in first-degree relatives. The sample
comprised 148 Caucasians, 6 Africans, 2 Asians, and 4 families of
mixed ethnicity (self-report). In addition, we tested a sample of 282
HGDP individuals: 106 from Asia, 87 from sub-Saharian Africa and
89 from Europe and the Middle East (Table S1).
DNA was obtained from blood leukocytes or B-lymphoblastoid
cell lines, and was extracted with phenol-chloroform. Mutations
were screened by direct sequencing of the PCR products with
specific primers (Table S2). We sequenced 17 coding exons of
SEZ6L2 (NM_201575.2) and one supplementary exon present in
the other isoform (NM_012410.2) that had not previously been
sequenced by Kumar et al. (2009). Amplification of 20 ng of DNA
template was performed using specific primers. Two PCR
protocols were used: (i) A standard protocol with the HotStart
Taq polymerase (Qiagen) was used for all exons except exons 4
and 5: 95uC for 15 min, followed by 35 cycles of 95uC for 30 s, 57
to 62uC (depending on the Tm) for 30 s, 72uC for 30 s to 1 min
(depending on the product size), with a final cycle at 72uC for
10 min; (ii) A Phusion High-Fidelity DNA polymerase (Finnzymes)
standard protocol was used for exons 4 and 5: 98uC for 3 min
followed by 35 cycles of 98uC for 10 s, 62uC for 25 s, and 72uC for
1 min, with a final cycle at 72uC for 10 min. Sequence analysis
was performed by direct sequencing of the PCR products using the
BigDye Terminator Cycle V3.1 Sequencing Kit, and an ABI
PRISM genetic analyzer (Applied Biosystems). For all non-
synonymous variations, the genotype was confirmed by sequenc-
ing an independent PCR product.
SEZ6L2 in Autism Spectrum Disorders
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